Supplementary Figure S15 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity | Synapse
August 1, 2024Open Access
Supplementary Figure S15 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.